US$ 27.56
what are the risks of glp-1 GLP-1: Diabetes Drug Changing How We Think About Weight Loss GLP-1 Agonist: The Good, the
Description
M., Rosenstock, J., Tran, M

The 2nd GLP-1-Based Therapeutics Summit returns to tackle the challenges in best-in-class GLP-1 development and indication expansion with new clinical data, new preclinical data, and 18+ expert speakers including Eli Lily, Regeneron, Roche, Novo Nordisk, Fractyl Health and more at the forefront of the field
Los agonistas de los receptores GLP-1 y GIP son tratamientos innovadores desarrollados inicialmente para la diabetes, pero que ahora se utilizan para tratar la obesidad

More doable
Explore Fyrtles fertility-focused GLP-1 guidance, designed to support metabolic wellness and enhance your reproductive health
